A clinical study to assess the effect of the mixture of recombinant human platelet derived growth factor (rhPDGF) and Beta tri calcium phosphate (Î²- TCP) in the treatment of periodontal intrabony defects.

Evaluation of the efficacy of 1:1 mixture of Î²-TCP and rhPDGF-BB in the surgical management of two and three wall intraosseous defects â?? a randomized controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/11/010554

Enrollment

Registered

2017-11-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Periodontitis

Interventions

Intervention1: Recombinant human platelet derived growth factor - BB and beta tricalcium phosphate.: Recombinant human platelet derived growth factor - BB mixed with beta tricalcium phosphate. Control

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1.Age: 20-60 years 2.Presence of at least one tooth on each side of the mouth with probing depth (PD) and clinical attachment loss (CAL) >= 5mm. 3.Radiographic evidence of interproximal intraosseous defect depth>=3mm.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1.Poor oral hygiene and poor patient compliance. 2.Smokers. 3.Pregnant and lactating women. 4.Patients with the study tooth exhibiting grade III mobility. 5.Patients with study tooth exhibiting furcation involvement of grade II or more. 6.Patients with any systemic diseases that contraindicate periodontal treatment 7.Patients with history of drug intake known to affect the periodontium i.e., systemic antibiotics and long term anti-inflammatory drugs during the last 6 months. 8.Patients with unmanageable occlusal dysfunction.

Design outcomes

Primary

Measure	Time frame
Amount and percentage of radiographic bone fill in the periodontal intraosseous defectTimepoint: 6months	—

Secondary

Measure	Time frame
Changes in probing depth. Changes in clinical attachment level. Amount of bone fill. Gingival recession. Timepoint: 3 and 6 months	—

Countries

India

Contacts

Public ContactDr N V S Sruthima G

Vishnu dental college

drsruthima@yahoo.co.in9492293808

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026